Evidence map›Paper›PMID 36386195›Full record

ArticleFrontiers in pharmacology2022

Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593.

Asher L Brandt, Sumanta Garai, Ayat Zagzoog, Dow P Hurst, Lesley A Stevenson, Roger G Pertwee, Gregory H Imler, Patricia H Reggio, Ganesh A Thakur, Robert B Laprairie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Carvone derived cannabidiol enantiomers as novel anticonvulsants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Asher L BrandtCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Sumanta GaraiDepartment of Pharmaceutical Sciences, Bouvé College of Health Sciences, Boston, MA, United States.
Ayat ZagzoogCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Dow P HurstCenter for Drug Discovery, University of North Carolina Greensboro, Greensboro, NC, United States.
Lesley A StevensonSchool of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
Roger G PertweeSchool of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland, United Kingdom.
Gregory H ImlerCentre for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC, United States.
Patricia H ReggioCenter for Drug Discovery, University of North Carolina Greensboro, Greensboro, NC, United States.
Ganesh A ThakurDepartment of Pharmaceutical Sciences, Bouvé College of Health Sciences, Boston, MA, United States.
Robert B LaprairieCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
University of Saskatchewan · CAUniversity of Aberdeen · GBUniversity of North Carolina at Greensboro · USUnited States Naval Research Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positive allosteric modulation of the type 1 cannabinoid receptor (CB1R) has substantial potential to treat both neurological and immune disorders. To date, a few studies have evaluated the structure-activity relationship (SAR) for CB1R positive allosteric modulators (PAMs). In this study, we separated the enantiomers of the previously characterized two potent CB1R ago-PAMs GAT591 and GAT593 to determine their biochemical activity at CB1R. Separating the enantiomers showed that the

Indexed as

allosteric agonistIn silico modelingmolecular mechanics-generalized born surface area (MMGBSA)molecular pharmacologypositive allosteric modulatortype 1 cannabinoid receptor (CB1R)

Identifiers

PMID36386195
PMCPMC9640980
OpenAlexW4307407244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.